Detlev Mennerich

Background

About Detlev Mennerich

I studied chemistry in Braunschweig (Germany) and Bordeaux (France) and i hold a PhD in cell and molecular biology. In 2001, i started my industrial career at metaGen Pharmaceuticals GmbH and Schering AG in Berlin (Germany) as a Scientist in Oncogenomics focusing on target validation and biomarker research. In 2005, i joined Boehringer Ingelheim Pharma GmbH & Co.KG in Biberach an der Riss (Germany), where i held several positions with increasing responsibilities: i started as laboratory head in Genomic Research for new drug concept nominations. In 2009, i moved to Ridgefield, CT (USA) as project leader for an anti-inflammatory antibody project. In 2011, i returned to Biberach heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation. Beginning of 2014, i joined the BI Venture Fund investing in clinical translation of pioneering therapeutic approaches, i.e. in the field of immuno-oncology, gene therapy and/or regenerative concepts. In this role, i represented BIVF in the Board of Directors at various biotech companies across EU and US, before i took over the role of the Global Head of Boehringer Ingelheim's Research Beyond Border (RBB) in 2020. As an important part of BI's external innovation strategy, RBB is present at all geographic areas scouting for emerging science for indications where the clinical practice has not changed since a decade. Since May 2022 i am heading Boehringer Ingelheim's partnering ambitions as Global Head of Business Development & Licensing.